Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
JNJ
Johnson & Johnson
$155.21
Chart
$157.01 (-1.15%)
$166.69 (-6.89%)
$146.64 (+5.84%)
$145.54 (+6.64%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
JNJ
Johnson & Johnson
Current Price
$155.21
Login to view Johnson & Johnson (JNJ) recommendation from the last 90 days from financial news and social media.
Chart
$157.01 (-1.15%)
$166.69 (-6.89%)
$146.64 (+5.84%)
$145.54 (+6.64%)
JNJ Latest Headlines
Johnson & Johnson (JNJ) Presents at the Bernsteins 41st Annual Strategic Decisions Conference (Transcript).
Wed May 28, 2025
Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth.
Tue May 27, 2025
Johnson &. Johnsons IMAAVY Gets FDA Approval Taking on Top Players in Myasthenia Gravis Market | DelveInsight. The FDA has approved Johnson & Johnsons anti-FcRn antibody nipocalimab for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval positions J&J to challenge leading competitors in the myasthenia gravis market such as...
Thu May 22, 2025
Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025. EMPOWER CAD a global prospective multi-center real-world study reaffirms favorable acute outcomes for coronary IVL in female patients unlike other calcium modification tools PARIS May 20 2025 /PRNewswire/ -- Shockwave Medical Inc. part of Johnson & Johnson MedTech and a global...
Tue May 20, 2025
Market Whales and Their Recent Bets on JNJ Options. Deep-pocketed investors have adopted a ish approach towards Johnson &. Johnson (NYSE:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in JNJ usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'
Mon May 19, 2025
New Analyst Forecast: $JNJ Given Buy Rating. We just received data on a new analyst forecast for $JNJ. Johnson Rice gave a rating of Buy for $JNJ.
Thu May 15, 2025
Barclays and J&J Snack Foods have been highlighted as Zacks and Bear of the Day. Barclays and J&J Snack Foods have been highlighted as Zacks and Bear of the Day.
Wed May 14, 2025
Bear of the Day: J&J Snack Foods (JJSF). Estimated sales growth of less than 2% for the current fiscal year implies a slowdown from recent trends.
Wed May 14, 2025
Bear of the Day: J&J Snack Foods (JJSF). Estimated sales growth of less than 2% for the current fiscal year implies a slowdown from recent trends.
Wed May 14, 2025
Noteworthy Tuesday Option Activity: NATL ABNB JNJ. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in NCR Atleos Corp (Symbol: NATL) where a total of 2117 contracts have traded so far representing approximately 211700 underlying shares. That amounts to about 52.4% of
Tue May 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
